PPARA and prostate carcinoma: In addition, PPAR agonists including troglitazone, rosiglitazone, ciglitazone and pioglitazone could inhibit proliferation of castration-sensitive (LNCaP) as well as castration-resistant (C4-2, PC-3 and DU145) prostate cancer cell lines [21–23].